Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Maze Therapeutics (MAZE) Shares Outstanding (Weighted Average) (2024 - 2026)

Maze Therapeutics' Shares Outstanding (Weighted Average) history spans 3 years, with the latest figure at $53.9 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 88.26% to $53.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $53.9 million, a 88.26% increase, with the full-year FY2025 number at $43.0 million, up 1693.59% from a year prior.
  • Shares Outstanding (Weighted Average) hit $53.9 million in Q1 2026 for Maze Therapeutics, up from $43.0 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for MAZE hit a ceiling of $53.9 million in Q1 2026 and a floor of $2.3 million in Q1 2024.
  • Historically, Shares Outstanding (Weighted Average) has averaged $24.1 million across 3 years, with a median of $28.6 million in 2025.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): surged 1820.19% in 2025 and later surged 88.26% in 2026.
  • Tracing MAZE's Shares Outstanding (Weighted Average) over 3 years: stood at $2.4 million in 2024, then soared by 1693.59% to $43.0 million in 2025, then grew by 25.41% to $53.9 million in 2026.
  • Business Quant data shows Shares Outstanding (Weighted Average) for MAZE at $53.9 million in Q1 2026, $43.0 million in Q4 2025, and $45.8 million in Q3 2025.